EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023

Navin Niranjan iD, Tracey Guan iD, Nitin Niranjan, Atefeh Taherian Fard, Danny R Youlden iD, Robert Mason, Bryan A Chan, Jasotha Sanmugarajah

Thoracic Cancer · 2026-04 · 17 (7)

DOI: 10.1111/1759-7714.70274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 29.03.2026. Verfasst von Navin Niranjan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gold Coast University Hospital, Southport, Queensland, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most commonly mutated oncogene in solid tumors, detected in up to 30% of lung adenocarcinomas. This study aimed to address gaps in the literature by analyzing KRAS mutations (KRASM) in a large Australian population.

Methods

A total of 3982 patients with metastatic nonsquamous nonsmall cell lung cancer diagnosed via public hospitals were retrospectively analyzed from January 1, 2014 to December 31, 2023. Records were reviewed for evidence of KRASM testing, KRAS results, biopsy type, and programmed death‐ligand 1 (PD‐L1) status. KRASM testing rates were also compared to that of other commonly tested oncogenic mutations.

Results

KRASM testing was performed in 52.9% of eligible patients, improving from 1.9% in 2014 to 86.3% in 2023. KRASM was identified in 830 patients (39.4% of KRASM tested patients, 20.8% overall). The most common KRASM seen was 12th codon substitution of KRAS glycine to cysteine (G12C) followed by substitutions of glycine to valine (G12V) and glycine to aspartate (G12D). Patients harboring KRASM were significantly more likely to have smoked, be female, and have higher PD‐L1 expression than their KRAS wild type (wt) counterparts. All‐cause survival was higher at the 1‐year (43.9% vs. 35.3%) and 5‐year (12.4% vs. 8.9%) marks in KRAS wt patients compared to KRAS mt.

Conclusion

This study is the largest longitudinal analysis of KRASM testing conducted in Australia, with significant improvement in testing rates seen over the time period. Rates of KRASM and characteristics of Australian KRAS mt patients correspond with published literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins p21(ras)Lung NeoplasmsMutationHumansFemaleMaleMiddle AgedAgedRetrospective StudiesQueenslandPrevalenceAged, 80 and overAdult

Stichwörter der Autor:innen

KRAS protein (human)molecular targeted therapynonsmall cell lung cancer

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Gold Coast University Hospital, Southport, Queensland, Australia.
  • School of Medicine and Dentistry, Griffith University, Southport, Queensland, Australia.
  • Department of Health, Metro South Hospital and Health Service, Cancer Alliance Queensland, Woolloongabba, Queensland, Australia.
  • Adem Crosby Cancer Centre, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
  • School of Medicine and Dentistry, Griffith University, Birtinya, Queensland, Australia.
  • Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia.

ORCID-Profile: Navin Niranjan, Tracey Guan, Danny R Youlden

Zitieren

APA

Niranjan, N., Guan, T., Niranjan, N., Taherian Fard, A., Youlden, D. R., Mason, R., Chan, B. A., & Sanmugarajah, J. (2026). Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023. Thoracic Cancer, 17(7). https://doi.org/10.1111/1759-7714.70274

Vancouver

Niranjan N, Guan T, Niranjan N, Taherian Fard A, Youlden DR, Mason R, et al. Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023. Thoracic Cancer. 2026;17(7). doi:10.1111/1759-7714.70274

BibTeX
@article{Niranjan2026,
  author = {Niranjan, Navin and Guan, Tracey and Niranjan, Nitin and Taherian Fard, Atefeh and Youlden, Danny R and Mason, Robert and Chan, Bryan A and Sanmugarajah, Jasotha},
  title = {Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Mutation Testing Trends, Prevalence, and Outcomes in Metastatic, Non‐Squamous Non‐Small Cell Lung Cancer (Non‐ SQ NSCLC ) Patients in Queensland, Australia From 2014–2023},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {7},
  doi = {10.1111/1759-7714.70274}
}
Kostenlos starten →